CD274 and non-small cell lung carcinoma: For example, pembrolizumab, a humanized monoclonal antibody against PD-1, plus platinum-based chemotherapy significantly improved overall survival rates of NSCLC patients with a PD-L1 ≥ 50% and negative for genomic alterations in the EGFR and ALK genes, compared with pembrolizumab monotherapy (19).